Press Releases CEL-SCI Corporation

Equities

CVM

US1508376076

Delayed Nyse Other stock markets 15:45:04 2024-05-14 EDT			5-day change	1st Jan Change
1.395 ^USD	-1.76%		-16.47%	-48.71%

05-08	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	MT
05-08	CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	05-09	AQ
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	05-08	BU
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	04-23	BU
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	03-19	BU
CEL-SCI Corporation Issues Letter to Shareholders	03-06	BU
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	02-15	BU
Cel-Sci: Fiscal Q1 Earnings Snapshot	02-14	AQ
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock	02-13	BU
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	02-12	AQ
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	02-09	BU
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head and Neck Cancer Drug	02-07	AQ
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	02-06	BU
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path towards Marketing Authorization for Multikine	02-01	AQ
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®	01-31	BU
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments	12-22	BU
UK'S National Institute for Health and Care Excellence Selects CEL-SCI's Multikine as Potential New Standard of Care for Head and Neck Cancer	12-05	AQ
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer	12-04	BU
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock	11-20	BU
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock	11-16	BU
CEL-SCI Issues Letter to Shareholders	23-10-30	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CEL-SCI Corporation

Equities

CVM

US1508376076

Press Releases

Filters